ID   RN146_HUMAN             Reviewed;         359 AA.
AC   Q9NTX7; E1P572; Q6FIB2; Q7L8H4; Q96K03; Q96T06; Q9NTX6;
DT   01-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   10-MAY-2017, entry version 140.
DE   RecName: Full=E3 ubiquitin-protein ligase RNF146;
DE            EC=2.3.2.27;
DE   AltName: Full=Dactylidin;
DE   AltName: Full=Iduna;
DE   AltName: Full=RING finger protein 146;
DE   AltName: Full=RING-type E3 ubiquitin transferase RNF146 {ECO:0000305};
GN   Name=RNF146;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND SUBCELLULAR LOCATION.
RC   TISSUE=Brain;
RX   PubMed=15813938; DOI=10.1111/j.1460-9568.2005.03977.x;
RA   von Rotz R.C., Kins S., Hipfel R., von der Kammer H., Nitsch R.M.;
RT   "The novel cytosolic RING finger protein dactylidin is up-regulated in
RT   brains of patients with Alzheimer's disease.";
RL   Eur. J. Neurosci. 21:1289-1298(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=11230166; DOI=10.1101/gr.GR1547R;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H.,
RA   Lauber J., Duesterhoeft A., Beyer A., Koehrer K., Strack N.,
RA   Mewes H.-W., Ottenwaelder B., Obermaier B., Tampe J., Heubner D.,
RA   Wambutt R., Korn B., Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and
RT   analysis of 500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Placenta, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   POSSIBLE INVOLVEMENT IN BREAST CANCER.
RX   PubMed=18326623; DOI=10.1073/pnas.0800441105;
RA   Gold B., Kirchhoff T., Stefanov S., Lautenberger J., Viale A.,
RA   Garber J., Friedman E., Narod S., Olshen A.B., Gregersen P.,
RA   Kosarin K., Olsh A., Bergeron J., Ellis N.A., Klein R.J., Clark A.G.,
RA   Norton L., Dean M., Boyd J., Offit K.;
RT   "Genome-wide association study provides evidence for a breast cancer
RT   risk locus at 6q22.33.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:4340-4345(2008).
RN   [9]
RP   POSSIBLE INVOLVEMENT IN BREAST CANCER.
RX   PubMed=19690183; DOI=10.1158/1055-9965.EPI-09-0151;
RA   Kirchhoff T., Chen Z.Q., Gold B., Pal P., Gaudet M.M., Kosarin K.,
RA   Levine D.A., Gregersen P., Spencer S., Harlan M., Robson M.,
RA   Klein R.J., Hudis C.A., Norton L., Dean M., Offit K.;
RT   "The 6q22.33 locus and breast cancer susceptibility.";
RL   Cancer Epidemiol. Biomarkers Prev. 18:2468-2475(2009).
RN   [10]
RP   POSSIBLE INVOLVEMENT IN BREAST CANCER.
RX   PubMed=19517271; DOI=10.1007/s10689-009-9255-7;
RA   Menachem T.D., Laitman Y., Kaufman B., Friedman E.;
RT   "The RNF146 and ECHDC1 genes as candidates for inherited breast and
RT   ovarian cancer in Jewish Ashkenazi women.";
RL   Fam. Cancer 8:399-402(2009).
RN   [11]
RP   POSSIBLE INVOLVEMENT IN BREAST CANCER.
RX   PubMed=21445572; DOI=10.1007/s10549-011-1459-5;
RA   Peng S., Lu B., Ruan W., Zhu Y., Sheng H., Lai M.;
RT   "Genetic polymorphisms and breast cancer risk: evidence from meta-
RT   analyses, pooled analyses, and genome-wide association studies.";
RL   Breast Cancer Res. Treat. 127:309-324(2011).
RN   [12]
RP   FUNCTION, PATHWAY, DOMAIN WWE, UBIQUITINATION, INTERACTION WITH AXIN1;
RP   AXIN2; CASC3 AND BLZF1, AND MUTAGENESIS OF ARG-163.
RX   PubMed=21478859; DOI=10.1038/ncb2222;
RA   Zhang Y., Liu S., Mickanin C., Feng Y., Charlat O., Michaud G.A.,
RA   Schirle M., Shi X., Hild M., Bauer A., Myer V.E., Finan P.M.,
RA   Porter J.A., Huang S.M., Cong F.;
RT   "RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin
RT   degradation and Wnt signalling.";
RL   Nat. Cell Biol. 13:623-629(2011).
RN   [13]
RP   FUNCTION IN NEUROPROTECTION.
RX   PubMed=21602803; DOI=10.1038/nm.2387;
RA   Andrabi S.A., Kang H.C., Haince J.F., Lee Y.I., Zhang J., Chi Z.,
RA   West A.B., Koehler R.C., Poirier G.G., Dawson T.M., Dawson V.L.;
RT   "Iduna protects the brain from glutamate excitotoxicity and stroke by
RT   interfering with poly(ADP-ribose) polymer-induced cell death.";
RL   Nat. Med. 17:692-699(2011).
RN   [14]
RP   FUNCTION IN WNT SIGNALING, INTERACTION WITH AXIN1; DDB1; DHX15;
RP   IQGAP1; LRPPRC; PARP1; PARP2; PRKDC; RUVBL2; TNKS1 AND TNKS2,
RP   UBIQUITINATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF HIS-54 AND
RP   TRP-106.
RX   PubMed=21799911; DOI=10.1371/journal.pone.0022595;
RA   Callow M.G., Tran H., Phu L., Lau T., Lee J., Sandoval W.N., Liu P.S.,
RA   Bheddah S., Tao J., Lill J.R., Hongo J.A., Davis D., Kirkpatrick D.S.,
RA   Polakis P., Costa M.;
RT   "Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt
RT   signaling.";
RL   PLoS ONE 6:E22595-E22595(2011).
RN   [15]
RP   FUNCTION IN DNA DAMAGE RESPONSE, HOMOOLIGOMERIZATION, INTERACTION WITH
RP   HIST1H1C; IPO7; LIG3; NCL; PARP1; XRCC1; XRCC5 AND XRCC6, SUBCELLULAR
RP   LOCATION, AND AUTOUBIQUITINATION AT LYS-85; LYS-95; LYS-131 AND
RP   LYS-176.
RX   PubMed=21825151; DOI=10.1073/pnas.1108799108;
RA   Kang H.C., Lee Y.I., Shin J.H., Andrabi S.A., Chi Z., Gagne J.P.,
RA   Lee Y., Ko H.S., Lee B.D., Poirier G.G., Dawson V.L., Dawson T.M.;
RT   "Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that
RT   regulates DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:14103-14108(2011).
RN   [16]
RP   STRUCTURE BY NMR OF 24-84.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the RING domain of the human RING finger
RT   protein 146.";
RL   Submitted (JUN-2006) to the PDB data bank.
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 100-184 IN COMPLEX WITH
RP   ISO-ADP-RIBOSE, FUNCTION, AND MUTAGENESIS OF TYR-108; ARG-111;
RP   TRP-115; TYR-145; GLN-154; ARG-164 AND LYS-176.
RX   PubMed=22267412; DOI=10.1101/gad.182618.111;
RA   Wang Z., Michaud G.A., Cheng Z., Zhang Y., Hinds T.R., Fan E.,
RA   Cong F., Xu W.;
RT   "Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE
RT   domains suggests a general mechanism for poly(ADP-ribosyl)ation-
RT   dependent ubiquitination.";
RL   Genes Dev. 26:235-240(2012).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that specifically binds
CC       poly-ADP-ribosylated (PARsylated) proteins and mediates their
CC       ubiquitination and subsequent degradation. May regulate many
CC       important biological processes, such as cell survival and DNA
CC       damage response. Acts as an activator of the Wnt signaling pathway
CC       by mediating the ubiquitination of PARsylated AXIN1 and AXIN2, 2
CC       key components of the beta-catenin destruction complex. Acts in
CC       cooperation with tankyrase proteins (TNKS and TNKS2), which
CC       mediate PARsylation of target proteins AXIN1, AXIN2, BLZF1, CASC3,
CC       TNKS and TNKS2. Recognizes and binds tankyrase-dependent
CC       PARsylated proteins via its WWE domain and mediates their
CC       ubiquitination, leading to their degradation. Different ubiquitin
CC       linkage types have been observed: TNKS2 undergoes ubiquitination
CC       at 'Lys-48' and 'Lys-63', while AXIN1 is only ubiquitinated at
CC       'Lys-48'. May regulate TNKS and TNKS2 subcellular location,
CC       preventing aggregation at a centrosomal location. Neuroprotective
CC       protein. Protects the brain against N-methyl-D-aspartate (NMDA)
CC       receptor-mediated glutamate excitotoxicity and ischemia, by
CC       interfering with PAR-induced cell death, called parthanatos.
CC       Prevents nuclear translocation of AIFM1 in a PAR-binding dependent
CC       manner. Does not affect PARP1 activation (By similarity). Protects
CC       against cell death induced by DNA damaging agents, such as N-
CC       methyl-N-nitro-N-nitrosoguanidine (MNNG) and rescues cells from G1
CC       arrest. Promotes cell survival after gamma-irradiation.
CC       Facilitates DNA repair. {ECO:0000250, ECO:0000269|PubMed:21478859,
CC       ECO:0000269|PubMed:21602803, ECO:0000269|PubMed:21799911,
CC       ECO:0000269|PubMed:21825151, ECO:0000269|PubMed:22267412}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:21478859}.
CC   -!- SUBUNIT: Can form homooligomers. Interacts with PARsylated AXIN1,
CC       AXIN2, BLZF1, CASC3, HIST1H1C, IPO7, LIG3, NCL, PARP1, XRCC1,
CC       XRCC5 and XRCC6. Interacts with DDB1, DHX15, IQGAP1, LRPPRC,
CC       PARP2, PRKDC, RUVBL2, TNKS1 and TNKS2. Binding often leads to
CC       interactor ubiquitination, in the presence of the appropriate E1
CC       and E2 enzymes, and proteasomal degradation.
CC       {ECO:0000269|PubMed:21478859, ECO:0000269|PubMed:21799911,
CC       ECO:0000269|PubMed:21825151, ECO:0000269|PubMed:22267412}.
CC   -!- INTERACTION:
CC       Q8N6L0:CCDC155; NbExp=4; IntAct=EBI-11750630, EBI-749265;
CC       Q12933:TRAF2; NbExp=3; IntAct=EBI-722397, EBI-355744;
CC       Q9UGJ1:TUBGCP4; NbExp=3; IntAct=EBI-722397, EBI-1052544;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Nucleus.
CC       Note=Translocates to the nucleus after DNA damage, such as laser-
CC       induced DNA breaks, and concentrates at DNA breaks. This
CC       translocation requires PARP1 activation and PAR-binding.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NTX7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NTX7-2; Sequence=VSP_012968;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Up-regulated in brains
CC       from patients with Alzheimer disease.
CC   -!- DOMAIN: The WWE domain mediates non-covalent PAR-binding.
CC       {ECO:0000269|PubMed:21478859}.
CC   -!- PTM: Ubiquitinated; autoubiquitinated. Polyubiquitinated in the
CC       presence of UBE2D1, UBE2D2 and UBE2D3. Multimonoubiquitinated in
CC       the presence of UBE2E1. Not ubiquitinated in the presence of
CC       UBE2H, CDC34, UBE2L3, UBE2L6, nor UBE2C. In the absence of PAR,
CC       autoubiquitination occurs on Lys-85, Lys-95 and Lys-176 via 'Lys-
CC       11' and 'Lys-48' ubiquitin linkages. In the presence of PAR, Lys-
CC       131 and Lys-176 are ubiquitinated via 'Lys-6', 'Lys-33' and 'Lys-
CC       48' ubiquitin linkages. Autoubiquitination is enhanced upon PAR-
CC       binding. {ECO:0000269|PubMed:21478859,
CC       ECO:0000269|PubMed:21799911, ECO:0000269|PubMed:21825151}.
CC   -!- DISEASE: Note=Defects in RNF146 are a cause of susceptibility to
CC       breast cancer.
CC   -!- MISCELLANEOUS: Was named dactylidin after the Greek term
CC       'daktylidi' for ring, 'the thing around the finger'
CC       (PubMed:15813938). Was named Iduna after the Norse goddess of
CC       protection and eternal youth (PubMed:21602803).
CC       {ECO:0000305|PubMed:15813938, ECO:0000305|PubMed:21602803}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ315122; CAC85986.1; -; mRNA.
DR   EMBL; AL136829; CAB66763.1; -; mRNA.
DR   EMBL; AK027558; BAB55196.1; -; mRNA.
DR   EMBL; AK027436; BAB55108.1; -; mRNA.
DR   EMBL; AK027776; BAB55359.1; -; mRNA.
DR   EMBL; CR533514; CAG38545.1; -; mRNA.
DR   EMBL; AL109939; CAB76254.1; -; Genomic_DNA.
DR   EMBL; AL109939; CAB76255.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48109.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48111.1; -; Genomic_DNA.
DR   EMBL; BC008235; AAH08235.1; -; mRNA.
DR   CCDS; CCDS5136.1; -. [Q9NTX7-2]
DR   CCDS; CCDS56449.1; -. [Q9NTX7-1]
DR   RefSeq; NP_001229773.1; NM_001242844.1. [Q9NTX7-2]
DR   RefSeq; NP_001229774.1; NM_001242845.1. [Q9NTX7-2]
DR   RefSeq; NP_001229775.1; NM_001242846.1. [Q9NTX7-2]
DR   RefSeq; NP_001229776.1; NM_001242847.1. [Q9NTX7-2]
DR   RefSeq; NP_001229777.1; NM_001242848.1. [Q9NTX7-2]
DR   RefSeq; NP_001229778.1; NM_001242849.1. [Q9NTX7-1]
DR   RefSeq; NP_001229779.1; NM_001242850.1. [Q9NTX7-1]
DR   RefSeq; NP_001229780.1; NM_001242851.1. [Q9NTX7-1]
DR   RefSeq; NP_001229781.1; NM_001242852.1. [Q9NTX7-2]
DR   RefSeq; NP_112225.2; NM_030963.3. [Q9NTX7-2]
DR   RefSeq; XP_006715634.1; XM_006715571.3. [Q9NTX7-2]
DR   RefSeq; XP_011534463.1; XM_011536161.2. [Q9NTX7-2]
DR   RefSeq; XP_011534464.1; XM_011536162.2. [Q9NTX7-2]
DR   RefSeq; XP_011534465.1; XM_011536163.2. [Q9NTX7-2]
DR   RefSeq; XP_011534466.1; XM_011536164.2. [Q9NTX7-2]
DR   RefSeq; XP_016866825.1; XM_017011336.1. [Q9NTX7-1]
DR   RefSeq; XP_016866826.1; XM_017011337.1. [Q9NTX7-2]
DR   RefSeq; XP_016866827.1; XM_017011338.1. [Q9NTX7-2]
DR   RefSeq; XP_016866828.1; XM_017011339.1. [Q9NTX7-2]
DR   RefSeq; XP_016866829.1; XM_017011340.1. [Q9NTX7-2]
DR   RefSeq; XP_016866830.1; XM_017011341.1. [Q9NTX7-2]
DR   RefSeq; XP_016866831.1; XM_017011342.1. [Q9NTX7-2]
DR   RefSeq; XP_016866832.1; XM_017011343.1. [Q9NTX7-2]
DR   UniGene; Hs.267120; -.
DR   PDB; 2D8T; NMR; -; A=27-84.
DR   PDB; 3V3L; X-ray; 1.65 A; A/B=100-184.
DR   PDBsum; 2D8T; -.
DR   PDBsum; 3V3L; -.
DR   ProteinModelPortal; Q9NTX7; -.
DR   SMR; Q9NTX7; -.
DR   BioGrid; 123598; 39.
DR   DIP; DIP-52730N; -.
DR   IntAct; Q9NTX7; 9.
DR   MINT; MINT-1370830; -.
DR   STRING; 9606.ENSP00000357297; -.
DR   iPTMnet; Q9NTX7; -.
DR   PhosphoSitePlus; Q9NTX7; -.
DR   BioMuta; RNF146; -.
DR   DMDM; 60390653; -.
DR   MaxQB; Q9NTX7; -.
DR   PaxDb; Q9NTX7; -.
DR   PeptideAtlas; Q9NTX7; -.
DR   PRIDE; Q9NTX7; -.
DR   DNASU; 81847; -.
DR   Ensembl; ENST00000309649; ENSP00000309365; ENSG00000118518. [Q9NTX7-2]
DR   Ensembl; ENST00000368314; ENSP00000357297; ENSG00000118518. [Q9NTX7-1]
DR   Ensembl; ENST00000608991; ENSP00000477168; ENSG00000118518. [Q9NTX7-2]
DR   Ensembl; ENST00000610153; ENSP00000476814; ENSG00000118518. [Q9NTX7-1]
DR   Ensembl; ENST00000616343; ENSP00000479890; ENSG00000118518. [Q9NTX7-1]
DR   GeneID; 81847; -.
DR   KEGG; hsa:81847; -.
DR   UCSC; uc003qav.4; human. [Q9NTX7-1]
DR   CTD; 81847; -.
DR   DisGeNET; 81847; -.
DR   GeneCards; RNF146; -.
DR   HGNC; HGNC:21336; RNF146.
DR   HPA; HPA027158; -.
DR   HPA; HPA027209; -.
DR   MIM; 612137; gene.
DR   neXtProt; NX_Q9NTX7; -.
DR   OpenTargets; ENSG00000118518; -.
DR   PharmGKB; PA134910489; -.
DR   eggNOG; KOG0824; Eukaryota.
DR   eggNOG; ENOG410ZTFC; LUCA.
DR   GeneTree; ENSGT00390000000358; -.
DR   HOVERGEN; HBG057514; -.
DR   InParanoid; Q9NTX7; -.
DR   KO; K15700; -.
DR   OMA; RMAGCGE; -.
DR   OrthoDB; EOG091G0Y4Y; -.
DR   PhylomeDB; Q9NTX7; -.
DR   TreeFam; TF318925; -.
DR   Reactome; R-HSA-201681; TCF dependent signaling in response to WNT.
DR   Reactome; R-HSA-4641257; Degradation of AXIN.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   UniPathway; UPA00143; -.
DR   EvolutionaryTrace; Q9NTX7; -.
DR   GeneWiki; RNF146; -.
DR   GenomeRNAi; 81847; -.
DR   PRO; PR:Q9NTX7; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000118518; -.
DR   CleanEx; HS_RNF146; -.
DR   ExpressionAtlas; Q9NTX7; baseline and differential.
DR   Genevisible; Q9NTX7; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0072572; F:poly-ADP-D-ribose binding; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; TAS:Reactome.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IMP:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0016055; P:Wnt signaling pathway; TAS:Reactome.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR033509; RNF146.
DR   InterPro; IPR004170; WWE-dom.
DR   InterPro; IPR018123; WWE-dom_subgr.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR13417:SF8; PTHR13417:SF8; 1.
DR   Pfam; PF02825; WWE; 1.
DR   SMART; SM00184; RING; 1.
DR   SMART; SM00678; WWE; 1.
DR   PROSITE; PS50918; WWE; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Wnt signaling pathway; Zinc; Zinc-finger.
FT   CHAIN         1    359       E3 ubiquitin-protein ligase RNF146.
FT                                /FTId=PRO_0000056107.
FT   DOMAIN       92    168       WWE. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00248}.
FT   ZN_FING      37     75       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   BINDING     108    108       iso-ADP-ribose adenine ring group.
FT                                {ECO:0000269|PubMed:22267412}.
FT   BINDING     111    111       iso-ADP-ribose 5'-phosphate group.
FT                                {ECO:0000269|PubMed:22267412}.
FT   BINDING     115    115       iso-ADP-ribose 5'-phosphate group.
FT                                {ECO:0000269|PubMed:22267412}.
FT   BINDING     145    145       iso-ADP-ribose 1'-phosphate group.
FT                                {ECO:0000269|PubMed:22267412}.
FT   BINDING     154    154       iso-ADP-ribose adenine ring group.
FT                                {ECO:0000269|PubMed:22267412}.
FT   BINDING     164    164       iso-ADP-ribose 1'-phosphate group.
FT                                {ECO:0000269|PubMed:22267412}.
FT   BINDING     176    176       iso-ADP-ribose 5'-phosphate group.
FT                                {ECO:0000269|PubMed:22267412}.
FT   MOD_RES     290    290       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q5XIK5}.
FT   MOD_RES     294    294       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q5XIK5}.
FT   CROSSLNK     85     85       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:21825151}.
FT   CROSSLNK     95     95       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:21825151}.
FT   CROSSLNK    131    131       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:21825151}.
FT   CROSSLNK    176    176       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:21825151}.
FT   VAR_SEQ       1      1       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11230166,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:15813938,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_012968.
FT   VARIANT      25     25       C -> R (in dbSNP:rs10081141).
FT                                /FTId=VAR_065249.
FT   MUTAGEN      54     54       H->A: Partially suppression of WNT3A
FT                                signaling and stabilization of AXIN1,
FT                                TNKS and TNKS2 with or without WNT3A
FT                                induction. No effect on TNKS1-binding.
FT                                {ECO:0000269|PubMed:21799911}.
FT   MUTAGEN     106    106       W->A: No effect on Wnt signaling pathway.
FT                                {ECO:0000269|PubMed:21799911}.
FT   MUTAGEN     108    108       Y->A: Loss of iso-ADP-ribose-binding.
FT                                {ECO:0000269|PubMed:22267412}.
FT   MUTAGEN     111    111       R->A: Minor effect on iso-ADP-ribose-
FT                                binding. {ECO:0000269|PubMed:22267412}.
FT   MUTAGEN     115    115       W->A: Strong decrease in iso-ADP-ribose-
FT                                binding affinity.
FT                                {ECO:0000269|PubMed:22267412}.
FT   MUTAGEN     145    145       Y->A: Loss of iso-ADP-ribose-binding.
FT                                {ECO:0000269|PubMed:22267412}.
FT   MUTAGEN     154    154       Q->A: Loss of iso-ADP-ribose-binding
FT                                affinity. {ECO:0000269|PubMed:22267412}.
FT   MUTAGEN     163    163       R->A: Abolishes the ability to recognize
FT                                and bind PARsylated proteins.
FT                                {ECO:0000269|PubMed:21478859}.
FT   MUTAGEN     164    164       R->A: Loss of iso-ADP-ribose-binding.
FT                                {ECO:0000269|PubMed:22267412}.
FT   MUTAGEN     176    176       K->A: Minor effect on iso-ADP-ribose-
FT                                binding. {ECO:0000269|PubMed:22267412}.
FT   CONFLICT     69     69       K -> R (in Ref. 3; BAB55359).
FT                                {ECO:0000305}.
FT   CONFLICT     74     74       C -> R (in Ref. 3; BAB55108).
FT                                {ECO:0000305}.
FT   CONFLICT    100    100       G -> E (in Ref. 4; CAG38545).
FT                                {ECO:0000305}.
FT   CONFLICT    166    166       I -> V (in Ref. 4; CAG38545).
FT                                {ECO:0000305}.
FT   CONFLICT    229    229       L -> S (in Ref. 3; BAB55108).
FT                                {ECO:0000305}.
FT   CONFLICT    329    329       S -> L (in Ref. 3; BAB55108).
FT                                {ECO:0000305}.
FT   STRAND       30     33       {ECO:0000244|PDB:2D8T}.
FT   STRAND       38     43       {ECO:0000244|PDB:2D8T}.
FT   STRAND       45     50       {ECO:0000244|PDB:2D8T}.
FT   TURN         51     53       {ECO:0000244|PDB:2D8T}.
FT   STRAND       54     57       {ECO:0000244|PDB:2D8T}.
FT   HELIX        58     63       {ECO:0000244|PDB:2D8T}.
FT   STRAND       68     70       {ECO:0000244|PDB:2D8T}.
FT   STRAND       72     74       {ECO:0000244|PDB:2D8T}.
FT   HELIX        80     83       {ECO:0000244|PDB:2D8T}.
FT   STRAND      104    109       {ECO:0000244|PDB:3V3L}.
FT   STRAND      111    116       {ECO:0000244|PDB:3V3L}.
FT   HELIX       119    130       {ECO:0000244|PDB:3V3L}.
FT   STRAND      134    140       {ECO:0000244|PDB:3V3L}.
FT   STRAND      143    148       {ECO:0000244|PDB:3V3L}.
FT   TURN        149    152       {ECO:0000244|PDB:3V3L}.
FT   STRAND      153    159       {ECO:0000244|PDB:3V3L}.
FT   STRAND      164    173       {ECO:0000244|PDB:3V3L}.
SQ   SEQUENCE   359 AA;  38950 MW;  7337C410EDA30A7E CRC64;
     MMAGCGEIDH SINMLPTNRK ANESCSNTAP SLTVPECAIC LQTCVHPVSL PCKHVFCYLC
     VKGASWLGKR CALCRQEIPE DFLDKPTLLS PEELKAASRG NGEYAWYYEG RNGWWQYDER
     TSRELEDAFS KGKKNTEMLI AGFLYVADLE NMVQYRRNEH GRRRKIKRDI IDIPKKGVAG
     LRLDCDANTV NLARESSADG ADSVSAQSGA SVQPLVSSVR PLTSVDGQLT SPATPSPDAS
     TSLEDSFAHL QLSGDNTAER SHRGEGEEDH ESPSSGRVPA PDTSIEETES DASSDSEDVS
     AVVAQHSLTQ QRLLVSNANQ TVPDRSDRSG TDRSVAGGGT VSVSVRSRRP DGQCTVTEV
//
